Community Practice Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer

Activity Overview

In hormone receptor–positive, HER2-negative advanced breast cancer, ESR1 mutations arise under the selective pressure of aromatase inhibitor therapy and confer resistance to the treatments most patients are already receiving. Yet, they are missed when testing relies on tissue alone or is drawn at the wrong time. The oral endocrine landscape has expanded rapidly: three oral agents are now approved, each restricted to ESR1-mutant disease detected by a companion diagnostic, whereas others remain investigational. The pivotal data separate sharply along mutation status, combination and monotherapy strategies suit different patients, and a circulating tumor DNA (ctDNA)–guided switch strategy has reported positive results ahead of regulatory action. As community oncologists navigate this landscape, correctly timed biomarker testing, biomarker-based treatment selection, and management of agent-specific monitoring requirements have become critical.

This Community Practice Connection™ program provides an in-depth review of ESR1 testing and oral endocrine therapy across the disease course in advanced breast cancer. This unique and engaging multimedia activity is ideal for the community-based clinician. It focuses on the practical interpretation of clinical trial data and on management strategies for ctDNA-based ESR1 testing, treatment selection among approved oral agents, combination and sequencing strategies, and shared decision-making in the community oncology setting. The program is designed for those who did not attend the live activity and to help reinforce learning for those who did.

Target Audience

This educational program is directed toward community-based medical oncologists, surgeons, advanced practice providers, nurses, and other health care professionals involved in the treatment of breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Develop biomarker-based diagnostic approaches to assess HR+/HER2– advanced breast cancer progression and identify optimal treatment options
• Assess clinical trial data for current and emerging agents for HR+/HER2– breast cancer and impact on the treatment paradigm for treatment plans
• Implement shared decision-making strategies to optimize adverse event management and enhance treatment adherence in clinical practice

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.